A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors von Tolcher, A.W., Papadopoulos, K.P., Patnaik, A., Wilson, K., Thayer, S., Zanghi, J., Gemo, A.T., Kavanaugh, W.M., Keer, H.N., LoRusso, P.M.

Volltext